{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:22:39Z","timestamp":1774437759244,"version":"3.50.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["U54NS065768"],"award-info":[{"award-number":["U54NS065768"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2020,4]]},"abstract":"\n Significance Statement<\/jats:title>\n In males with classic Fabry disease, the processes leading to the frequent outcome of ESKD are poorly understood. Mutations in the gene encoding \u03b1<\/jats:italic>-galactosidase A leads to globotriaosylceramide accumulation in various cell types; in podocytes, this accumulation progresses with age. In this study of 55 males with classic Fabry disease genotype and\/or phenotype, the authors found an increasing fraction of podocyte cytoplasm occupied by globotriaosylceramide, which plateaued at around the age of 27 years. At the same time, podocyte volume continued to rise, apparently at the expense of increasing podocyte stress (indicated by increasing podocyte foot process width) and podocyte loss. These changes associated with increasing urinary protein excretion, a strong prognosticator of adverse renal outcomes, and with reduction in GFR, indicating a need for early intervention before critical podocyte loss.<\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n In males with classic Fabry disease, the processes leading to the frequent outcome of ESKD are poorly understood. Defects in the gene encoding \u03b1<\/jats:italic>-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types. In the glomerular podocytes, accumulation of GL3 progresses with age. Of concern, podocytes are relatively resistant to enzyme replacement therapy and are poorly replicating, with little ability to compensate for cell loss.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In this study of 55 males (mean age 27 years) with classic Fabry disease genotype and\/or phenotype, we performed unbiased quantitative morphometric electron microscopic studies of biopsied kidney samples from patients and seven living transplant donors (to serve as controls). We extracted clinical information from medical records and clinical trial databases.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Podocyte GL3 volume fraction (proportion of podocyte cytoplasm occupied by GL3) increased with age up to about age 27, suggesting that increasing podocyte GL3 volume fraction beyond a threshold may compromise survival of these cells. GL3 accumulation was associated with podocyte injury and loss, as evidenced by increased foot process width (a generally accepted structural marker of podocyte stress and injury) and with decreased podocyte number density per glomerular volume. Worsening podocyte structural parameters (increasing podocyte GL3 volume fraction and foot process width) was also associated with increasing urinary protein excretion\u2014a strong prognosticator of adverse renal outcomes in Fabry disease\u2014as well as with decreasing GFR.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Given the known association between podocyte loss and irreversible FSGS and global glomerulosclerosis, this study points to an important role for podocyte injury and loss in the progression of Fabry nephropathy and indicates a need for therapeutic intervention before critical podocyte loss occurs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.2019050497","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T22:05:51Z","timestamp":1583273151000},"page":"865-875","source":"Crossref","is-referenced-by-count":75,"title":["Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss"],"prefix":"10.1681","volume":"31","author":[{"given":"Behzad","family":"Najafian","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle, Washington;"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Haukland University Hospital, Bergen, Norway;"},{"name":"Institute of Clinical Medicine, University of Bergen, Bergen, Norway;"}]},{"given":"Einar","family":"Svarstad","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Bergen, Bergen, Norway;"}]},{"given":"Marie-Claire","family":"Gubler","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1163, Imagine Institute, Necker\u2013Enfants Malades Hospital, Paris, France;"}]},{"given":"Jo\u00e3o-Paulo","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Service of Medical Genetics, S\u00e3o Jo\u00e3o University Hospital, Porto, Portugal;"},{"name":"Department of Medical Genetics, Faculty of Medicine, i3S (Institute for Research and Innovation in Health), University of Porto, Porto, Portugal;"}]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota; and"},{"name":"Department of Medicine, University of Minnesota, Minneapolis, Minnesota"}]}],"member":"276","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"B1-20231107","first-page":"157","article-title":"Fabry\u2019s disease: Enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes","volume":"81","author":"Desnick","year":"1973","journal-title":"J Lab Clin Med"},{"key":"B2-20231107","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"B3-20231107","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"B4-20231107","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B5-20231107","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"B6-20231107","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: Role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B7-20231107","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ajpath.2013.06.033","article-title":"New insights into the pathology of podocyte loss: Mitotic catastrophe","volume":"183","author":"Liapis","year":"2013","journal-title":"Am J Pathol"},{"key":"B8-20231107","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: Natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 6","key":"B9-20231107","first-page":"vi39","article-title":"The pathogenesis of \u2018classic\u2019 focal segmental glomerulosclerosis-lessons from rat models","volume":"18","author":"Kriz","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"B10-20231107","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1523-1755.2005.67097.x","article-title":"Pathways to nephron loss starting from glomerular diseases-insights from animal models","volume":"67","author":"Kriz","year":"2005","journal-title":"Kidney Int"},{"key":"B11-20231107","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int"},{"key":"B12-20231107","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease","volume":"101","author":"Patel","year":"2015","journal-title":"Heart"},{"key":"B13-20231107","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: Data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J Med Genet"},{"key":"B14-20231107","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.clinbiochem.2012.04.030","article-title":"Comparison between alpha-galactosidase A activity in blood samples collected on filter paper, leukocytes and plasma","volume":"45","author":"Daitx","year":"2012","journal-title":"Clin Biochem"},{"key":"B15-20231107","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"key":"B16-20231107","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med 155: 408, 2011]","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B17-20231107","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/000992288602501106","article-title":"Reliability of plasma creatinine measurement in infants and children","volume":"25","author":"Clermont","year":"1986","journal-title":"Clin Pediatr (Phila)"},{"key":"B18-20231107","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN)","volume":"25","author":"Fogo","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"B19-20231107","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2818.1985.tb02607.x","article-title":"Stereological estimation of the volume-weighted mean volume of arbitrary particles observed on random sections","volume":"138","author":"Gundersen","year":"1985","journal-title":"J Microsc"},{"key":"B20-20231107","doi-asserted-by":"crossref","first-page":"e0152812","DOI":"10.1371\/journal.pone.0152812","article-title":"One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in male adult patients with fabry disease","volume":"11","author":"Najafian","year":"2016","journal-title":"PLoS One"},{"key":"B21-20231107","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1681\/ASN.2018111166","article-title":"Changes in albuminuria but not GFR are associated with early changes in kidney structure in type 2 diabetes","volume":"30","author":"Looker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B22-20231107","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.2337\/db07-0019","article-title":"Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy","volume":"56","author":"Toyoda","year":"2007","journal-title":"Diabetes"},{"key":"B23-20231107","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/ki.2015.152","article-title":"Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis","volume":"88","author":"Eng","year":"2015","journal-title":"Kidney Int"},{"key":"B24-20231107","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00424-011-0954-1","article-title":"Intercellular and extracellular mechanotransduction in cardiac myocytes","volume":"462","author":"Kresh","year":"2011","journal-title":"Pflugers Arch"},{"key":"B25-20231107","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-005-0089-x","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement","volume":"448","author":"Schiffmann","year":"2006","journal-title":"Virchows Arch"},{"key":"B26-20231107","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"B27-20231107","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1083\/jcb.201410017","article-title":"Review series: The cell biology of renal filtration","volume":"209","author":"Scott","year":"2015","journal-title":"J Cell Biol"},{"key":"B28-20231107","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1681\/ASN.2014080752","article-title":"Glomerular aging and focal global glomerulosclerosis: A podometric perspective","volume":"26","author":"Hodgin","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B29-20231107","doi-asserted-by":"crossref","first-page":"e0168346","DOI":"10.1371\/journal.pone.0168346","article-title":"Urinary podocyte loss is increased in patients with fabry disease and correlates with clinical severity of fabry nephropathy","volume":"11","author":"Fall","year":"2016","journal-title":"PLoS One"},{"key":"B30-20231107","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40620-016-0271-z","article-title":"Podocyturia is significantly elevated in untreated vs treated Fabry adult patients","volume":"29","author":"Trimarchi","year":"2016","journal-title":"J Nephrol"},{"key":"B31-20231107","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.nefro.2018.05.009","article-title":"Podocyturia in paediatric patients with Fabry disease","volume":"39","author":"Liern","year":"2019","journal-title":"Nefrologia"},{"key":"B32-20231107","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1681\/ASN.2005050488","article-title":"Podocyte hypertrophy, \u201cadaptation,\u201d and \u201cdecompensation\u201d associated with glomerular enlargement and glomerulosclerosis in the aging rat: Prevention by calorie restriction","volume":"16","author":"Wiggins","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B33-20231107","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1681\/ASN.2017020174","article-title":"FSGS as an adaptive response to growth-induced podocyte stress","volume":"28","author":"Nishizono","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B34-20231107","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Sanchez-Ni\u00f1o","year":"2015","journal-title":"Hum Mol Genet"},{"key":"B35-20231107","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3390\/jcm7110409","article-title":"Oxidative stress and cardiovascular-renal damage in fabry disease: Is there room for a pathophysiological involvement?","volume":"7","author":"Ravarotto","year":"2018","journal-title":"J Clin Med"},{"key":"B36-20231107","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00441-017-2609-9","article-title":"Pathomechanisms of renal Fabry disease","volume":"369","author":"Eikrem","year":"2017","journal-title":"Cell Tissue Res"},{"key":"B37-20231107","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2019.03.010","article-title":"Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial","volume":"127","author":"Ramaswami","year":"2019","journal-title":"Mol Genet Metab"},{"key":"B38-20231107","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/jmedgenet-2017-104826","article-title":"Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment","volume":"54","author":"Mauer","year":"2017","journal-title":"J Med Genet"},{"key":"B39-20231107","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent agalsidase effects on kidney histology in fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B40-20231107","first-page":"807","article-title":"Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients","volume":"32","author":"Skrunes","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B41-20231107","doi-asserted-by":"crossref","first-page":"e112188","DOI":"10.1371\/journal.pone.0112188","article-title":"Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease","volume":"9","author":"Mauer","year":"2014","journal-title":"PLoS One"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1681\/ASN.2019050497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T20:09:36Z","timestamp":1699387776000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1681\/ASN.2019050497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2019050497","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]}}}